Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306186 | 0.76 | ALDH1A1 (0.35) | SLC22A12ALDH1A1HSD17B10P2RX7 | |
| SCHEMBL761996 | 0.76 | ALDH1A1 (0.41) | ADORA2AADORA1SLC22A12ALDH1A1HSD17B10 | |
| SCHEMBL3185104 | 0.73 | DYRK1A (0.35) | ADORA2AADORA1ALDH1A1HSD17B10P2RX7 | |
| SCHEMBL18876099 | 0.73 | P2RX7 (0.34) | ALDH1A1HSD17B10P2RX7 | |
| SCHEMBL30002369 | 0.73 | P2RX7 (0.36) | ALDH1A1HSD17B10P2RX7TGFBR1 | |
| SCHEMBL4075607 | 0.73 | ALDH1A1 (0.33) | ALDH1A1HSD17B10P2RX7 | |
| SCHEMBL2722669 | 0.72 | ALDH1A1 (0.46) | SLC22A12ALDH1A1HSD17B10 | |
| SCHEMBL12157070 | 0.71 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL20043206 | 0.69 | CASR (0.33) | ADORA2AADORA1ALDH1A1 | |
| SCHEMBL3173531 | 0.69 | CDK1 (0.33) | ALDH1A1HSD17B10P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | ADORA2A 1308/4885ADORA1 1742/4885SLC22A12 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.